Ramez N. Eskander, MD

Ramez N. Eskander, MD, is an assistant professor in the Departments of Obstetrics, Gynecology, and Reproductive Sciences at the University of California (UC) San Diego School of Medicine; as well as the director for oncology of the clinical trials office at the UC San Diego Moores Cancer Center

Articles

Oncology Experts Discuss the Long-Term Effects of the COVID-19 Pandemic: With Ramez N. Eskander, MD; Rachel N. Grisham, MD; Benjamin Herzberg, MD; Kelly McCann, MD, PhD; and Gregory Roloff, MD

March 31st 2025

Experts from across oncology specialties discuss the long-term effects of the COVID-19 pandemic on patient care.

Dr Eskander on the Potential Clinical Benefit of Nivolumab in dMMR Endometrial Cancer

March 27th 2025

Ramez N. Eskander, MD, discusses the key efficacy findings and future implications of the NIVEC trial of nivolumab in resectable dMMR endometrial cancer.

Dr Eskander on Pembrolizumab Plus Chemo in Advanced/Recurrent Endometrial Cancer

April 24th 2024

Ramez N. Eskander, MD, discusses overall survival data for pembrolizumab plus chemotherapy in advanced/recurrent endometrial cancer.

The Future of Clinical Care for Patients With Advanced Endometrial Cancer

October 6th 2023

Closing their conversation, Ramez Eskander, MD, and Krishnansu Tewari, MD, share how they envision the future treatment landscape for patients with advanced endometrial cancer.

Emerging Targeted Treatment Options for Patients With Advanced Endometrial Cancer

October 6th 2023

Key opinion leaders discuss targeted treatment regimens for advanced or recurrent endometrial cancer that are currently under development.

Patient Profile Presentation: A 68-Year-Old Woman With Recurrent Endometrial Cancer

September 29th 2023

Krishnansu Tewari, MD, presents the profile of a 68-year-old postmenopausal woman with recurrent endometrial cancer for discussion.

Approaches to Treatment Sequencing for Patients With Advanced Endometrial Cancer

September 29th 2023

Experts explain how they change their treatment strategies if a patient with advanced endometrial cancer does not respond to treatment or experiences disease progression.

Recent Data on IO-Based Combination Regimens for First-line Treatment of Advanced Endometrial Carcinoma

September 22nd 2023

Krishnansu Tewari, MD, reviews emerging data from two studies investigating immunotherapy-based combination regimens for the first-line treatment of advanced endometrial cancer.

Available Frontline Treatment Options for Patients With Advanced or Recurrent Endometrial Cancer

September 22nd 2023

Krishnansu Tewari, MD, details the first-line treatment options for patients with recurrent endometrial cancer.

Patient Profile Presentation: A 64-Year-Old Woman With Recurrent Endometrial Cancer

September 15th 2023

Ramez Eskander, MD, presents the profile of a 64-year-old postmenopausal woman diagnosed with recurrent endometrial carcinoma for discussion.

Overview of Endometrial Carcinoma

September 15th 2023

Ramez Eskander, MD, and Krishnansu Tewari, MD, provide an overview of endometrial cancer, including prevalence, staging criteria, and molecular profiling.

Dr Eskander on Pembrolizumab Plus Paclitaxel and Carboplatin in Endometrial Cancer

March 28th 2023

Ramez N. Eskander, MD, discusses findings from the phase 3 NRG GY018 trial of pembrolizumab plus chemotherapy in patients with endometrial cancer.

Ongoing Clinical Trials for Patients With Endometrial Cancer: Looking Toward the Future

April 5th 2022

Experts highlight key ongoing trials and emerging therapies for patients with endometrial cancer.

Management of Adverse Events After Combination Lenvatinib/Pembrolizumab

March 29th 2022

Shared insight on the management of commonly observed adverse events in patients with endometrial cancer who are receiving combination lenvatinib/pembrolizumab.

Treatment Modification Rates for Combination Lenvatinib/Pembrolizumab

March 29th 2022

A brief review of treatment interruption, discontinuation, and dose modification rates in patients receiving combination lenvatinib/pembrolizumab in the KEYNOTE-775 trial or in the experts’ clinical practice.

The KEYNOTE-775 Trial: Efficacy of Combination Lenvatinib/Pembrolizumab in Endometrial Cancer

March 22nd 2022

Vicky Makker, MD, leads a discussion of efficacy data from the KEYNOTE-775 trial on combination lenvatinib/pembrolizumab in patients with endometrial cancer.

First-line Treatment Options for Advanced Endometrial Cancer

March 22nd 2022

A comprehensive overview of first-line treatment options for patients with advanced endometrial cancer.

Molecular Testing in Endometrial Cancer

March 15th 2022

Experts discuss how molecular testing can inform treatment selection and patient management for those with endometrial cancer.

Endometrial Cancer: A Global Problem

March 15th 2022

Vicky Makker, MD and Ramez Eskander, MD discuss the increasing global incidence of endometrial cancer.

Dr. Eskander on the Utility of Lymphadenectomy in Endometrial Cancer

August 25th 2021

Ramez N. Eskander, MD, discusses the utility of lymphadenectomy in patients with endometrial cancer.